JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.66 -1.19

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.63

Max

1.72

Põhinäitajad
By Trading Economics
Sissetulek	13M -43M
Kasumimarginaal	-2,190.837
Töötajad	171
EBITDA	17M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+59.52% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. nov 2025

Turustatistika
By TradingEconomics
Turukapital	6.8M 111M
Eelmine avamishind	2.85
Eelmine sulgemishind	1.66

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. nov 2025, 21:44 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3. nov 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3. nov 2025, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3. nov 2025, 23:28 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3. nov 2025, 23:24 UTC

Tulu

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. nov 2025, 23:14 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

3. nov 2025, 23:14 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3. nov 2025, 23:12 UTC

Tulu

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3. nov 2025, 23:06 UTC

Market Talk

Tulu

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3. nov 2025, 22:36 UTC

Market Talk

Tulu

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3. nov 2025, 22:31 UTC

Tulu

Franco-Nevada 3Q EPS $1.49 >FNV

3. nov 2025, 22:31 UTC

Tulu

Franco-Nevada 3Q Rev $487.7M >FNV

3. nov 2025, 22:24 UTC

Market Talk

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3. nov 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Starbucks Agrees to Sell Stake in China Business -- WSJ

3. nov 2025, 21:59 UTC

Market Talk

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3. nov 2025, 21:54 UTC

Market Talk

Tulu

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3. nov 2025, 21:54 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

3. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. nov 2025, 21:49 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3. nov 2025, 21:40 UTC

Tulu

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3. nov 2025, 21:31 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3. nov 2025, 21:19 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3. nov 2025, 21:11 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3. nov 2025, 21:11 UTC

Tulu

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3. nov 2025, 21:07 UTC

Tulu

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3. nov 2025, 21:05 UTC

Tulu

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3. nov 2025, 21:05 UTC

Tulu

Palantir Technologies 3Q Net $475.6M >PLTR

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

59.52% tõus

12 kuu keskmine prognoos

Keskmine 2.68 USD 59.52%

Kõrge 4 USD

Madal 1.7 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.